Work

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma

Year: 2013

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v122.21.1947.1947

Authors: Irene M. Ghobrial, Kenneth Shain, Courtney Hanlon, Ranjit Banwait, Abdel Kareem Azab, Jacob P. Laubach, Philippe Armand, Nikhil C. Munshi, Robert L Schlossman, Stacey Chuma, Erica N Boswell, Patrick Mostyn, Leblebjian Houry, Kenneth C. Anderson, Paul G. Richardson

Institutions: Dana-Farber Cancer Institute, Moffitt Cancer Center, Harvard University, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4251280919

FWCI: 0.637

Cites:

Cited by: 5

Related to: 10